The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) guidelines which have been recently updated, strongly recommend IL-23 inhibitors for PsA patients, while the recommendation for IL-23 use in patients with peripheral arthritis is weaker [36]. This evidence concerns the gene IL37 and psoriatic arthritis.